|
|
 |
 |
Creating Value from Diversity |
 |
 |
For Schering-Plough,
innovation has become a primary differentiator
and driver of performance. We believe that
diversity fuels innovation.
Research shows that a multicultural work force offers
a richer variety of approaches to work-related problems
and processes. Ensuring that a diversity of opinions,
experiences, cultures and perspectives are represented,
and fostering an environment that allows them to flourish,
creates the essential breeding ground for innovation.
As we focus our research efforts on developing innovative
medicines, we are at the same time focused on finding ways
to maximize the potential of our own diverse work force.
By doing so, we're creating value from our diversity.
This philosophy - looking at diversity as an essential
driver of our success - has led us to dedicate ourselves
to the following vision and mission:
Diversity and inclusion vision - A new kind of
health care company, best among its peers, that is
global in structure and outlook, diverse and inclusive
in its culture
Diversity and inclusion mission - To build leadership
and organizational capacity and capability to create
value out of our global dimensions of diversity and inclusion
|
 |
 |
|
 |
 |
 |
 |
 |
 |
| |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
 |
| |
Chairman and CEO:
Fred Hassan |
 |
| |
Number of employees:
55,000 |
 |
 |
| |
Net sales (2007):
$12.7 billion |
 |
 |
| |
Business operations in more than:
140 countries |
 |
| |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
 |
| |
R&D investment
(2007):
$2.9 billion |
 |
| |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
 |
|
 |
 |
 |
|